Skip to main content
Erschienen in: Clinical Rheumatology 1/2011

01.03.2011

The economic burden of rheumatoid arthritis: beyond health care costs

verfasst von: Wei Zhang, Aslam H. Anis

Erschienen in: Clinical Rheumatology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) not only causes significant morbidity, but also leads to substantial losses in terms of productivity that have a negative impact on the individual and the society. In countries, such as Canada, the US, and the UK, it is known that the costs to the economy in terms of sick leave and work-related disability run into billions of dollars. However, putting an accurate figure on these losses is not entirely straightforward. Most health-related studies use the “human capital” approach, which treats human beings as assets. A figure for lost productivity is calculated by multiplying hours lost by the hourly wage rate. It is a method that is not without its critics because of its emphasis on earning power, which discriminates against non-earners. Another method is the “friction-cost” approach, whereby absenteeism is only recorded if the missed work requires extra hours undertaken, either by the employee himself, or by the others. A third method is the “willingness-to-pay” approach which values life according to an individual's preference to avoid illness with an imputed monetary valuation on the various health outcomes being considered. A number of studies have shown that biologic RA treatments provide productivity benefits in terms of maintaining employment, as well as reducing absenteeism and presenteeism. Going forward, an approach recently adopted by the present authors with encouraging preliminary results, the Valuation of Lost Productivity, takes into account a wide range of factors to provide a measure of productivity that is as accurate as possible.
Literatur
1.
Zurück zum Zitat Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22:1–12PubMedCrossRef Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22:1–12PubMedCrossRef
3.
Zurück zum Zitat Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8:S49–S60PubMedCrossRef Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8:S49–S60PubMedCrossRef
4.
5.
Zurück zum Zitat Hunsche E, Chancellor JV, Bruce N (2001) The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics 19:1–15PubMedCrossRef Hunsche E, Chancellor JV, Bruce N (2001) The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics 19:1–15PubMedCrossRef
6.
Zurück zum Zitat Health Canada (2003) Arthritis in Canada: An Ongoing Challenge. Cat. # H39-4/14-2003E Health Canada (2003) Arthritis in Canada: An Ongoing Challenge. Cat. # H39-4/14-2003E
7.
Zurück zum Zitat CDC (2007) National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. MMWR 56:4–7 CDC (2007) National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. MMWR 56:4–7
8.
Zurück zum Zitat National Audit Office (2009) Services for people with rheumatoid arthritis. Report by the comptroller and auditor general, HC 823 session 2008–2009. National Audit Office, 15 July 2009 National Audit Office (2009) Services for people with rheumatoid arthritis. Report by the comptroller and auditor general, HC 823 session 2008–2009. National Audit Office, 15 July 2009
9.
Zurück zum Zitat Johannesson M (1996) The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 36:231–244PubMedCrossRef Johannesson M (1996) The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 36:231–244PubMedCrossRef
10.
Zurück zum Zitat Berger ML, Murray JF, Xu J, Pauly M (2001) Alternative valuations of work loss and productivity. J Occup Environ Med 43:18–24PubMedCrossRef Berger ML, Murray JF, Xu J, Pauly M (2001) Alternative valuations of work loss and productivity. J Occup Environ Med 43:18–24PubMedCrossRef
11.
Zurück zum Zitat Pauly MV, Nicholson S, Xu J, Polsky D, Danzon PM (2002) A general model of the impact of absenteeism on employers and employees. Health Econ 11:221–231PubMedCrossRef Pauly MV, Nicholson S, Xu J, Polsky D, Danzon PM (2002) A general model of the impact of absenteeism on employers and employees. Health Econ 11:221–231PubMedCrossRef
12.
Zurück zum Zitat Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML (2006) Measuring the effects of work loss on productivity with team production. Health Econ 15:111–123PubMedCrossRef Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML (2006) Measuring the effects of work loss on productivity with team production. Health Econ 15:111–123PubMedCrossRef
13.
Zurück zum Zitat Pauly MV, Nicholson S, Polsky D, Berger ML, Sharda C (2008) Valuing reductions in on-the-job illness: ‘presenteeism’ from managerial and economic perspectives. Health Econ 17:469–485PubMedCrossRef Pauly MV, Nicholson S, Polsky D, Berger ML, Sharda C (2008) Valuing reductions in on-the-job illness: ‘presenteeism’ from managerial and economic perspectives. Health Econ 17:469–485PubMedCrossRef
14.
Zurück zum Zitat Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14:171–189PubMedCrossRef Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14:171–189PubMedCrossRef
15.
Zurück zum Zitat Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 14:435–443PubMedCrossRef Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 14:435–443PubMedCrossRef
16.
Zurück zum Zitat Olsen JA, Smith RD (2001) Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ 10:39–52PubMedCrossRef Olsen JA, Smith RD (2001) Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ 10:39–52PubMedCrossRef
17.
Zurück zum Zitat Zhang W, Bansbank N, Anis AH. Measuring and valuing productivity loss due to poor health: a review. Soc Sci Med (in press) Zhang W, Bansbank N, Anis AH. Measuring and valuing productivity loss due to poor health: a review. Soc Sci Med (in press)
18.
Zurück zum Zitat Clarke AE, Zowall H, Levinton C et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051–1060PubMed Clarke AE, Zowall H, Levinton C et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051–1060PubMed
19.
Zurück zum Zitat Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W (2001) Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 44:528–534PubMedCrossRef Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W (2001) Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 44:528–534PubMedCrossRef
20.
Zurück zum Zitat Yelin E (1996) The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 44:47–51PubMed Yelin E (1996) The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 44:47–51PubMed
21.
Zurück zum Zitat Yelin E, Cisternas M, Pasta D, Trupin L (2003) Direct and indirect costs of musculoskeletal conditions in 1997: Total and incremental estimates. Centers for Disease Control and Prevention, Atlanta Yelin E, Cisternas M, Pasta D, Trupin L (2003) Direct and indirect costs of musculoskeletal conditions in 1997: Total and incremental estimates. Centers for Disease Control and Prevention, Atlanta
22.
Zurück zum Zitat Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA (2002) The Work Limitations Questionnaire’s validity and reliability among patients with osteoarthritis. J Clin Epidemiol 55:197–208PubMedCrossRef Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA (2002) The Work Limitations Questionnaire’s validity and reliability among patients with osteoarthritis. J Clin Epidemiol 55:197–208PubMedCrossRef
23.
Zurück zum Zitat Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Community Hypertension and Arthritis Project Study Team (2004) The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 63:395–401PubMedCrossRef Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Community Hypertension and Arthritis Project Study Team (2004) The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 63:395–401PubMedCrossRef
24.
Zurück zum Zitat Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R (2003) Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290:2443–2454PubMedCrossRef Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R (2003) Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290:2443–2454PubMedCrossRef
25.
Zurück zum Zitat Li X, Gignac MA, Anis AH (2006) The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 44:304–310PubMedCrossRef Li X, Gignac MA, Anis AH (2006) The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 44:304–310PubMedCrossRef
26.
Zurück zum Zitat Zhang W, Koehoorn M, Anis AH (2010) Work productivity among employed Canadians with arthritis. J Occup Environ Med 52:872–877PubMedCrossRef Zhang W, Koehoorn M, Anis AH (2010) Work productivity among employed Canadians with arthritis. J Occup Environ Med 52:872–877PubMedCrossRef
27.
Zurück zum Zitat Gignac MA, Badley EM, Lacaille D, Cott CC, Adam P, Anis AH (2004) Managing arthritis and employment: making arthritis-related work changes as a means of adaptation. Arthritis Rheum 51:909–916PubMedCrossRef Gignac MA, Badley EM, Lacaille D, Cott CC, Adam P, Anis AH (2004) Managing arthritis and employment: making arthritis-related work changes as a means of adaptation. Arthritis Rheum 51:909–916PubMedCrossRef
28.
Zurück zum Zitat Gabriel SE, Crowson CS, Campion ME, O’Fallon WM (1997) Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 24:43–48PubMed Gabriel SE, Crowson CS, Campion ME, O’Fallon WM (1997) Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 24:43–48PubMed
29.
Zurück zum Zitat Yelin E, Henke C, Epstein W (1987) The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 30:507–512PubMedCrossRef Yelin E, Henke C, Epstein W (1987) The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 30:507–512PubMedCrossRef
30.
Zurück zum Zitat Yelin E, Sonneborn D, Trupin L (2000) The prevalence and impact of accommodations on the employment of persons 51–61 years of age with musculoskeletal conditions. Arthritis Care Res 13:168–176PubMedCrossRef Yelin E, Sonneborn D, Trupin L (2000) The prevalence and impact of accommodations on the employment of persons 51–61 years of age with musculoskeletal conditions. Arthritis Care Res 13:168–176PubMedCrossRef
31.
Zurück zum Zitat Reisine S, Fifield J, Walsh SJ, Feinn R (2001) Factors associated with continued employment among patients with rheumatoid arthritis: a survival model. J Rheumatol 28:2400–2408PubMed Reisine S, Fifield J, Walsh SJ, Feinn R (2001) Factors associated with continued employment among patients with rheumatoid arthritis: a survival model. J Rheumatol 28:2400–2408PubMed
32.
Zurück zum Zitat Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L (2003) Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 48:3046–3054PubMedCrossRef Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L (2003) Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 48:3046–3054PubMedCrossRef
33.
Zurück zum Zitat Bejarano V, Quinn MA, Conaghan PG et al (2007) Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis: results of the Prevention Of Work Disability (PROWD) Study. Ann Rheum Dis 66(Suppl II):176 Bejarano V, Quinn MA, Conaghan PG et al (2007) Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis: results of the Prevention Of Work Disability (PROWD) Study. Ann Rheum Dis 66(Suppl II):176
34.
Zurück zum Zitat Smolen JS, Han C, van der Heijde D et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722PubMedCrossRef Smolen JS, Han C, van der Heijde D et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722PubMedCrossRef
35.
Zurück zum Zitat Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF (2010) Rheumatoid arthritis (RA) patients treated with TNF-antagonists increase their participation in the work-force—potential for significant long-term indirect cost gains. Data from a population-based registry. Ann Rheum Dis 69:126–131PubMedCrossRef Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF (2010) Rheumatoid arthritis (RA) patients treated with TNF-antagonists increase their participation in the work-force—potential for significant long-term indirect cost gains. Data from a population-based registry. Ann Rheum Dis 69:126–131PubMedCrossRef
36.
Zurück zum Zitat van den Hout WB, Goekoop-Ruiterman YP, Allaart CF et al (2009) Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 61:291–299PubMedCrossRef van den Hout WB, Goekoop-Ruiterman YP, Allaart CF et al (2009) Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 61:291–299PubMedCrossRef
37.
Zurück zum Zitat Anis A, Zhang W, Emery P et al (2009) The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology 8:1283–1289CrossRef Anis A, Zhang W, Emery P et al (2009) The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology 8:1283–1289CrossRef
38.
Zurück zum Zitat Zhang W, Bansbank N, Guh D et al (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed Zhang W, Bansbank N, Guh D et al (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed
39.
Zurück zum Zitat Loeppke R, Hymel PA, Lofland JH et al (2003) Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. J Occup Environ Med 45:349–359PubMedCrossRef Loeppke R, Hymel PA, Lofland JH et al (2003) Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. J Occup Environ Med 45:349–359PubMedCrossRef
40.
Zurück zum Zitat Prasad M, Wahlqvist P, Shikiar R, Shih YC (2004) A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 22:225–244PubMedCrossRef Prasad M, Wahlqvist P, Shikiar R, Shih YC (2004) A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 22:225–244PubMedCrossRef
41.
Zurück zum Zitat Lofland JH, Pizzi L, Frick KD (2004) A review of health-related workplace productivity loss instruments. Pharmacoeconomics 22:165–184PubMedCrossRef Lofland JH, Pizzi L, Frick KD (2004) A review of health-related workplace productivity loss instruments. Pharmacoeconomics 22:165–184PubMedCrossRef
42.
Zurück zum Zitat Mattke S, Balakrishnan A, Bergamo G, Newberry SJ (2007) A review of methods to measure health-related productivity loss. Am J Manag Care 13:211–217PubMed Mattke S, Balakrishnan A, Bergamo G, Newberry SJ (2007) A review of methods to measure health-related productivity loss. Am J Manag Care 13:211–217PubMed
43.
Zurück zum Zitat Escorpizo R, Bombardier C, Boonen A et al (2007) Worker productivity outcome measures in arthritis. J Rheumatol 34:1372–1380PubMed Escorpizo R, Bombardier C, Boonen A et al (2007) Worker productivity outcome measures in arthritis. J Rheumatol 34:1372–1380PubMed
44.
Zurück zum Zitat Zhang W, Gignac MAM, Beaton D, Tang K, Anis AH, On behalf of the Canadian Arthritis Network Work Productivity Group (2010) Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol 37:1805–1814PubMedCrossRef Zhang W, Gignac MAM, Beaton D, Tang K, Anis AH, On behalf of the Canadian Arthritis Network Work Productivity Group (2010) Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol 37:1805–1814PubMedCrossRef
45.
Zurück zum Zitat Zhang W, Bansback N, Kiely P, Williams R, Walsh D, Young A, Anis AH (2010) Measuring work time loss among patients with rheumatoid arthritis: validating the valuation of lost productivity (VOLP) questionnaire. Ann Rheum Dis 69(Suppl3):467 Zhang W, Bansback N, Kiely P, Williams R, Walsh D, Young A, Anis AH (2010) Measuring work time loss among patients with rheumatoid arthritis: validating the valuation of lost productivity (VOLP) questionnaire. Ann Rheum Dis 69(Suppl3):467
46.
Zurück zum Zitat Kennedy I (2009) Appraising the value of innovation and other benefits—a short study for NICE. NICE, London Kennedy I (2009) Appraising the value of innovation and other benefits—a short study for NICE. NICE, London
Metadaten
Titel
The economic burden of rheumatoid arthritis: beyond health care costs
verfasst von
Wei Zhang
Aslam H. Anis
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe Sonderheft 1/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1637-6

Weitere Artikel der Sonderheft 1/2011

Clinical Rheumatology 1/2011 Zur Ausgabe

Introduction

Introduction

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.